Showing results (931-940 of 1,095) with videos related to

Sort By:
Pageof 110
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological FactorsSara Pilotto, Isabella Sperduti, Silvia Novello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2020
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 TrialMakoto Nishio, Fabrice Barlesi, Howard West, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2015
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung CancerGiorgio Scagliotti, Joachim von Pawel, Silvia Novello, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 16, 2026
Repeatability of semi-quantitative [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT measurements in pancreatobiliary cancers: a test-retest studyRutger B Henrar, Matthijs C F Cysouw, Xavier Palard-Novello, et al.
Natural Product Research|December 10, 2019
Dimeric glycosylated flavan-3-ol and antimicrobial <i>in vitro</i> evaluation of <i>Trichilia catigua</i> extractsMariane Roberta Ritter, Oliveira Marcelo Tempesta de, Regina Yasuko Makimori, et al.
Investigational New Drugs|June 29, 2016
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancerGiorgio Scagliotti, Jin Hyoung Kang, David Smith, et al.
The Lancet. Oncology|June 13, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trialAlice T Shaw, Tae Min Kim, Lucio Crinò, et al.
Nature Ecology & Evolution|June 19, 2019
Climate change and cultural resilience in late pre-Columbian AmazoniaJonas Gregorio de Souza, Mark Robinson, S Yoshi Maezumi, et al.
Therapeutic Advances in Medical Oncology|November 12, 2025
PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevanceSara Pilotto, Lorenzo Belluomini, Federico Monaca, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 1, 2025
Assessment of fully quantitative and simplified methods for analysis of [<sup>68</sup>Ga]Ga-FAPI-46 uptake in patients with pancreatobiliary cancer using LAFOV PET/CTXavier Palard-Novello, Rutger B Henrar, Daniela E Oprea-Lager, et al.
Pageof 110